Can Gilead And Merck Capitalize On AstraZeneca/Daiichi Sankyo’s TROP2 Safety Concerns?

Dato-DXd’s Lung Adverse Events Could Scupper NSCLC Goals

 
• By Andrew McConaghie

AstraZeneca and Daiichi-Sankyo’s second collaboration has taken a knock after a mixed readout from the TROPION-Lung01 study of their antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), and its rivals will hope their differently engineered ADCs can win out in the long-term.

Gilead_USA
Gilead's Trodelvy is the first TROP2 ADC on the market - Dato-DXd could still outperform it in breast cancer, but safety issues may hamper its progress in NSCLC

More from Clinical Trials

More from R&D